[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-368167-105":59,"doc-detail-368167-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","rare-epithelial-gastric-cancers-a-review-of-the-current-treatment-knowledge","Rare Epithelial Gastric Cancers - A Review of the Current Treatment Knowledge","","Gastric cancer is a leading cause of cancer mortality worldwide and is not a single uniform disease. Rare epithelial gastric tumours represent about 5% of epithelial cases, with incidence below 6 cases per 100,000 per year and distinct histology, biological behaviour, and clinical patterns. A narrative review synthesizes limited literature evidence to translate treatment knowledge into daily clinical practice through precision medicine, emphasizing biomarker-driven personalization. Clinicians should also support trial enrolment and international collaborations.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/rare-epithelial-gastric-cancers-a-review-of-the-current-treatment-knowledge/368167/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/rare-epithelial-gastric-cancers-a-review-of-the-current-treatment-knowledge/368167.png","ImageObject",300,407,{"name":92,"@type":93},"Lucas Martin","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-24","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":24},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why are rare epithelial gastric cancers difficult to study and treat?","Question",{"text":112,"@type":113},"Their incidence is low (fewer than 6 cases per 100,000 per year), limiting available evidence, including guidance on how histology affects prognosis and treatment response.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How does the review frame treatment decisions for rare gastric cancers?",{"text":117,"@type":113},"It emphasizes tailoring cures using the precision medicine concept, translating scarce literature evidence into daily clinical practice.",{"name":119,"@type":110,"acceptedAnswer":120},"Which rare gastric cancer subtypes are specifically highlighted in the review?",{"text":121,"@type":113},"The review focuses on rare gastric adenocarcinomas (including hepatoid adenocarcinoma, medullary carcinoma with lymphoid stroma, Paneth cell carcinoma, and salivary gland carcinoma), plus squamous cell carcinoma, adenosquamous carcinoma, neuroendocrine gastric neoplasms, and gastroblastoma.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},368167,1790889419,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":24,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},8796095360427,"https://ap-avatar.wpscdn.com/davatar_994ba38a5ba835b3df7d355c54d3ed8d","Rare epithelial gastric cancers: a review of the current treatment knowledge  \nAngelica Petrillo*, Margaret Ottaviano*, Luca Pompella, Emilio Francesco Giunta,  \nPasquale Pisapia, Gianpaolo Marte, Andrea Tufo, Sara Di Lorenzo, Jessica Orefice, Chiara Miceli, Umberto Malapelle, Bruno Daniele and Ferdinando De Vita  \nAbstract: Gastric cancer (GC), one of the tumours with the highest mortality worldwide, isnot a homogeneous disease, showing different features according to location, macroscopic aspect, histotype and molecular alterations. Adenocarcinoma is the most frequent epithelial GC (95%), the remaining 5% comprising rare epithelial tumours with their peculiarities, behaviour and incidence \u003C6 cases/100,000/year. Due to the low number of cases, many aspects must be elucidated in this context. In this narrative review, we highlight the importance of a better understanding of rare GCs to personalize the cures in the light of the precision medicine concept. Our main aim is to translate the scarce evidence from the literature into daily clinical practice, never forgetting that all the clinicians dedicated to rare GCs should encourage such patients’ enrolment in clinical trials and promote international collaborations. Hence, we focused on the treatment of the following rare GCs: rare gastric adenocarcinomas (hepatoid adenocarcinoma, medullary carcinoma with lymphoid stroma, Paneth cell carcinoma and Salivary Gland carcinoma); squamous cell carcinoma; adenosquamous carcinoma; neuroendocrine gastric neoplasms; gastroblastoma.  \nKeywords: adenosquamous carcinoma, Epstein–Barr virus, gastroblastoma, GEP-NEN, hepatoid adenocarcinoma, microsatellite instability, neuroendocrine gastric tumours, Paneth cell carcinoma and the Salivary Gland carcinoma, rare gastric adenocarcinomas, squamous cell carcinoma, the medullary carcinoma with lymphoid stroma  \nReceived: 22 August 2023; revised manuscript accepted: 30 April 2024.  \nIntroduction  \nGastric cancer (GC) is one of the tumours with the highest mortality worldwide, especially in Western countries.1 If the screening programmes allow the identification of tumours at a very early stage in Asian countries, the diagnosis is often late in the West. Additionally, in the case of non-metastatic tumours treated with curative surgery, the rate of relapses is high.2  \nIn this context, the search for prognostic and predictive biomarkers is the main goal to persuade to tailor the treatment for GC and improve the outcomes.3 Indeed, GC is not a homogeneous disease, showing different characteristics according to location, macroscopic aspect, histotype and molecular alterations. However, if several data  \nshowed that GC has its peculiarities according to the location (distal versus proximal tumours)4 as well as molecular classifications,5,6 the role of histology needs to be defined. In this regard, the World Health Organization (WHO) provided GC’s most comprehensive histological classification.7 According to that, adenocarcinomas are the most frequent epithelial GC (95%); they can also be classified according to Lauren’s classification from the histological point of view.8  \nNevertheless, 5% of GCs are rare epithelial tumours with peculiarities, behaviour and incidence, as per definition, of \u003C6 cases/100,000/ year. In this context, how the histology might affect the prognosis and the response to treatment (predictive role) is unclear, mainly due to the low  \nTherAdv Med Oncol 2025, Vol. 17: 1–23  \nDOI: 10. 1177/ 17588359241255628 © The Author(s), 2025.  \nArticle reuse guidelines: [sagepub.com/journals](sagepub.com/journals)permissions  \nCorrespondence to:  \nAngelica Petrillo  \nMedical Oncology Unit, Ospedale del Mare, Via E. Russo, Naples 80147, Italy  \n[angeli.petrillo@gmail.com](angeli.petrillo@gmail.com)  \nMargaret Ottaviano  \nDepartment of Melanoma, Cancer Immunotherapy and Development Therapeutics, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Naples, Italy  \nLuca Pompella  \nMedical Oncology Unit","cbCaipcDmhhcDBT8","https://ap.wps.com/l/cbCaipcDmhhcDBT8","pdf",958664,23,"English","# Introduction\n## Gastric cancer heterogeneity and diagnostic timing\n## Need for prognostic and predictive biomarkers\n# Histological classification and rationale for rare epithelial tumours\n## WHO classification and Lauren’s system\n## Incidence, behaviour, and prognostic uncertainty\n# Scope of rare epithelial gastric cancers covered","[{\"question\":\"Why are rare epithelial gastric cancers difficult to study and treat?\",\"answer\":\"Their incidence is low (fewer than 6 cases per 100,000 per year), limiting available evidence, including guidance on how histology affects prognosis and treatment response.\"},{\"question\":\"How does the review frame treatment decisions for rare gastric cancers?\",\"answer\":\"It emphasizes tailoring cures using the precision medicine concept, translating scarce literature evidence into daily clinical practice.\"},{\"question\":\"Which rare gastric cancer subtypes are specifically highlighted in the review?\",\"answer\":\"The review focuses on rare gastric adenocarcinomas (including hepatoid adenocarcinoma, medullary carcinoma with lymphoid stroma, Paneth cell carcinoma, and salivary gland carcinoma), plus squamous cell carcinoma, adenosquamous carcinoma, neuroendocrine gastric neoplasms, and gastroblastoma.\"}]","Rare Epithelial Gastric Cancers - A Review of the Current Treatment Knowledge | PDF",1790175392,58,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/dc34926333ea41f5d288bd1bbce5a44e.webp",983,1310,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/67e9b79206a1d6430443d81aaba6aeef.webp",982,1309,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bec341fff912d5d1b7a72bd620f113b5.webp",981,1308,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/683ca0744548e65617fa948804b2d30b.webp",980,1306]